Indoco Remedies received final approval for its ANDA for Febuxostat tablets 40 mg and 80 mg, which is therapeutically equivalent to the drug manufactured by Takeda Pharmaceuticals USA Inc. The market size of Febuxostat tablets in the US is over $500 million. Febuxostat is used for the treatment of gout caused by excessive levels of uric acid in the blood (Hyperuricemia). Febuxostat prevents production of uric acid by blocking the activity of the enzyme (xanthine oxidase) that converts purines to uric acid. Uric acid forms crystals in joints and tissues. Shares of Indoco Remedies down 0.42 per cent at ₹191.60 on the BSE.
Thank you for being a loyal user of Portfolio.
Portfolio will be a paid section hereon.
Please Subscribe to get access to one of our early bird packs.
Or click on Free Trial to get 14 days free trial.
What You'll Get
-
All Access Plan
Get Full Digital Access To The Hindu BusinessLine, The Hindu, Frontline, Sportstar, Crossword+, Epaper replica of The Hindu and The Hindu BusinessLine in ONE SINGLE DISCOUNTED PRICE!
-
Exclusive Portfolio
Get diverse set of perspectives from our trusted experts on Portfolio, Banking, Economy, Environment and others.
-
Web + Mobile
Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.
-
Ad free experience
Experience cleaner site with zero ads and faster load times.
-
Personalised dashboard
Customize your preference and get a personalized recommendation of stories based on your interest.
Published on
January 01, 2020
Please Email the Editor